Similar articles

• The FDA's assessment of two drugs for chronic weight management.

  Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. Colman E, et al. N Engl J Med. 2012 Oct 25;367(17):1577-9. doi: 10.1056/NEJMp1211277. Epub 2012 Oct 10. N Engl J Med. 2012. PMID: 23050510 No abstract available.
• Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird.

  Rubio MA. Rubio MA. Endocrinol Nutr. 2014 Dec;61(10):501-4. doi: 10.1016/j.endonu.2014.11.002. Endocrinol Nutr. 2014. PMID: 25434595 English, Spanish. No abstract available.
• New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).

  Shyh G, Cheng-Lai A. Shyh G, et al. Cardiol Rev. 2014 Jan-Feb;22(1):43-50. doi: 10.1097/CRD.0000000000000001. Cardiol Rev. 2014. PMID: 24304809 Review.
• Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.

  Bays H. Bays H. Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1777-801. doi: 10.1586/erc.10.125. Epub 2010 Aug 16. Expert Rev Cardiovasc Ther. 2010. PMID: 20707765 Review.
• Two anti-obesity hopefuls and their safety.

  Bello NT, Campbell SC. Bello NT, et al. Expert Opin Drug Saf. 2012 Sep;11(5):681-3. doi: 10.1517/14740338.2012.706277. Epub 2012 Jul 13. Expert Opin Drug Saf. 2012. PMID: 22788876 No abstract available.